Author

Leonard S. Dove 1

1 Former employee of FuriePharmaceuticals, an Allergan affiliate, Jersey City, United States of America

1-MONTH TREATMENT WITH ELUXADOLINE FOR IBS-D PREDICTS SUSTAINED RESPONSE: CONTINUATION ANALYSES OF RESPONSE IN TWO PHASE 3 STUDIES

William D. Chey, David A. Andrae, Leonard S. Dove, Catherine R. Gutman, Paul S. Covington

CONSISTENCY IN EFFICACY OUTCOMES OF ELUXADOLINE-TREATED PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA USING RECENT AND TRADITIONAL ENDPOINTS

Marc J. Zuckerman, Leonard S. Dove, David A. Andrae, J. Michael Davenport, Lisa Turner, Rocio Lopez, Paul S. Covington

EFFECTS OF ELUXADOLINE ON ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA: RESULTS OF TWO PHASE 3 TRIALS

Anthony J. Lembo, Leonard S. Dove, David A. Andrae, Lisa Turner, J. Michael Davenport, Paul S. Covington

ELUXADOLINE DEMONSTRATES SUSTAINED EFFICACY FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHOEA IN PHASE 3 CLINICAL TRIALS

William D. Chey, Leonard S. Dove, David A. Andrae, J. Michael Davenport, Lisa Turner, Rocio Lopez, Paul S. Covington

ROBUSTNESS OF ELUXADOLINE FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHOEA: RESULTS FROM PHASE 3 COMPOSITE ENDPOINT ASSESSMENTS

Brian Lacy, Leonard S. Dove, David A. Andrae, J. Michael Davenport, Lisa Turner, Rocio Lopez, Paul S. Covington

Item 1 - 5 / 5
1